Podcast: Play in new window | Download (Duration: 39:06 — 29.9MB) | Embed
Subscribe to the Healthcare Beans Podcast: Apple Podcasts | Spotify | RSS | Subscribe via..
In this episode of Healthcare Beans, James speaks with Ryan Polselli, MD, founder and CEO of MammoLink, about why breast cancer screening remains underused despite decades of awareness, established clinical guidance, and broad insurance coverage.
Ryan argues that the core problem is not simply awareness. Screening often conflicts with work, family responsibilities, appointment availability, financial uncertainty, and the natural tendency to postpone preventive care when no symptoms are present. He explains how MammoLink brings mammography and ultrasound directly to workplaces, schools, government sites, and rural communities through patient-centered mobile imaging units.
The conversation also explores price transparency, payer quality incentives, direct-pay demand, rural health infrastructure, employer-sponsored screening, nationwide expansion, and the role of data and emerging technologies in the future of breast cancer detection.
Episode Timeline
- 00:00 — Introduction to Ryan Polselli and MammoLink
Ryan introduces his background as a board-certified radiologist and breast-imaging specialist and describes his focus on improving access to breast cancer screening. - 01:02 — The breast cancer screening paradox
Despite widespread awareness and strong evidence supporting screening, many women still do not receive regular mammograms. Ryan explains why awareness alone has not produced sufficient action. - 03:35 — Where the screening process breaks down
The discussion examines the balance between personal responsibility and system responsibility, including the burdens created by work, family obligations, and limited appointment availability. - 04:56 — Designing preventive care around human behavior
Ryan contrasts urgent medical care with preventive screening. When patients feel healthy, completing screening requires a proactive decision without the emotional urgency that drives emergency care. - 06:06 — Making screening compatible with everyday life
Ryan argues that screening must be redesigned around how women actually live rather than requiring patients to navigate numerous scheduling and logistical barriers. - 07:12 — Financial barriers and uncertainty
Insurance may cover a routine mammogram, but patients can still face uncertainty involving supplemental imaging, dense breast tissue, diagnostic follow-up, and unexpected bills. - 09:23 — Delayed results and lost momentum
Long waits for results can increase anxiety and weaken engagement. Ryan explains why faster feedback can restore patient control and encourage better screening habits. - 10:39 — From patient experience to systems change
MammoLink began as an effort to improve the individual screening experience but evolved into a broader model connecting patient behavior, economics, employer interests, and payer incentives. - 13:04 — How the mobile imaging model works
Ryan describes mobile units containing mammography, ultrasound, changing areas, procedure rooms, and other features typically found in an outpatient imaging center. - 13:55 — Bringing screening into workplaces and communities
Recurring visits to schools, employers, municipalities, and government sites allow patients to receive screening where they already spend their time. - 14:20 — Social reinforcement and screening adherence
Coworkers can encourage one another to participate, while returning to the same location each year can make regular screening easier to remember and complete. - 16:09 — The economics of mobile mammography
Mobile screening carries higher capital and operating costs than traditional outpatient imaging, but Ryan describes it as a high-cost, high-yield model capable of reaching populations that might otherwise remain unscreened. - 17:00 — Legislative and payer tailwinds
Coverage changes involving supplemental breast imaging, along with growing payer interest, may improve the economic viability of comprehensive mobile screening. - 18:27 — Access is also about time
Ryan emphasizes that patients can be disadvantaged by limited time and flexibility even when they are not financially disadvantaged. - 19:54 — Incentives within traditional imaging pathways
The conversation considers how fee-for-service payment can encourage separate visits, while a mobile model has stronger operational reasons to complete as much of the episode as possible in one encounter. - 21:02 — HEDIS measures and payer motivation
Ryan explains how quality measures and Medicare Advantage star ratings can create significant incentives for health plans to improve breast cancer screening rates. - 22:27 — MammoLink’s no-surprise-billing approach
Ryan describes the company’s decision not to send patients an unexpected bill after the visit, even when that means accepting some lost revenue. - 25:05 — Technology supporting payment verification
MammoLink is using automated insurance-verification technology to improve up-front accuracy while preserving its principle of no back-end patient billing. - 25:30 — Can transparency increase competition?
The discussion turns to whether better consumer awareness of price differences between hospitals, outpatient centers, and alternative providers can eventually place downward pressure on costs. - 26:46 — Direct pay, privacy, and convenience
Ryan discusses the growing number of patients who choose cash payment because they value privacy, simplicity, or freedom from insurance-related friction. - 27:51 — Supporting patients after an abnormal finding
MammoLink manages diagnostic evaluation up to the point of biopsy and is developing stronger relationships with breast surgeons and health systems to improve downstream handoffs. - 29:55 — The rural breast-imaging access gap
Ryan describes rural communities where mammography may not be available locally and where patients can postpone evaluating a concerning symptom for long periods. - 30:40 — Public-sector and community partnerships
MammoLink works with the Florida Department of Health, migrant health organizations, and other partners to bring screening into underserved areas. - 31:52 — Rural transformation funding as infrastructure capital
Ryan and James discuss whether public funding could cover the initial cost of mobile units while allowing the operating model to become sustainable without permanent subsidy. - 33:13 — Expanding beyond Florida
Ryan outlines a potential national growth strategy involving grants, outside investment, and targeted entry into cities or states with favorable conditions. - 33:55 — Bootstrapping five mobile units
Ryan discusses building the company without outside venture funding and reflects on the effort required to create its existing mobile fleet. - 34:22 — The future of patient-centered mobile screening
Ryan distinguishes genuinely patient-centered mobile care from simply relocating a traditional service and argues that future expansion will depend on proving outcomes and financial value. - 35:30 — Demonstrating employer return on investment
The conversation explores using clinical, operational, employee, and geospatial data to help employers measure cancers detected, time saved, employee satisfaction, and potential avoided costs. - 37:05 — Employers as a preventive-care access channel
Ryan predicts that employers could play a larger role in providing screening as they seek to strengthen benefits, workforce health, retention, and trust. - 37:38 — AI and emerging breast-cancer detection tools
Ryan discusses research involving AI, biological markers, RNA-based technologies, and other emerging tools that may complement mammography and genetic screening. - 38:39 — No mission without margin
The episode closes with a reflection on why healthcare innovation must be economically sustainable to achieve lasting scale and impact.
Godspeed..
James
Note: Some statistics and estimates discussed in this episode were provided conversationally by the host or guest and may be approximate. They have not all been independently verified by Healthcare Beans. Listeners should consult current primary sources before relying on specific figures for medical, policy, or business decisions.
